<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0901233077
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2003
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AROMASIN 25MG COATED TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EXEMESTANE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        303.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PFIZER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02BG06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your medicine is called Aromasin. Aromasin belongs to a group of medicines known as aromatase inhibitors. These medicines interfere with a substance called aromatase, which is needed to make the female sex hormones, oestrogens, especially in postmenopausal women. Reduction in oestrogen levels in the body is a way of treating hormone dependent breast cancer.</p><p>&nbsp;</p><p>Aromasin is used to treat hormone dependent early breast cancer in postmenopausal women after they have completed 2-3 years of treatment with the medicine tamoxifen.</p><p>&nbsp;</p><p>Aromasin is also used to treat hormone dependent advanced breast cancer in postmenopausal women when a different hormonal drug treatment has not worked well enough.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Aromasin:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are or have previously been allergic to exemestane (the active ingredient in Aromasin) or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have<strong> not</strong> already been through &lsquo;the menopause&rsquo;, i.e. you are still having your monthly period.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant, likely to be pregnant or breast-feeding.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor, pharmacist or nurse before taking Aromasin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before treatment with Aromasin, your doctor may want to take blood samples to make sure you have reached the menopause.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Routine checking of your vitamin D level will also be made before treatment, as your level may be very low in the early stages of breast cancer. You will be given vitamin D supplement if your levels are below normal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before taking Aromasin, tell your doctor if you have problems with your liver or kidneys.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you have a history or are suffering from any condition which affects the strength of your bones. Your doctor may want to measure your bone density before and during the treatment of Aromasin. This is because medicines of this class lower the levels of female hormones and this may lead to a loss of the mineral content of bones, which might decrease their strength.</p><p>&nbsp;</p><p>Other medicines and Aromasin</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription<em>.</em></p><p>&nbsp;</p><p>Aromasin should not be given at the same time as hormone replacement therapy (HRT).</p><p>&nbsp;</p><p>The following medicines should be used cautiously when taking Aromasin. Let your doctor know if you are taking medicines such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (an antibiotic),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine or phenytoin (anticonvulsants used to treat epilepsy),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the herbal remedy St John&rsquo;s Wort (Hypericum perforatum), or preparations containing it.</p><p>&nbsp;</p><p><u>For those who carry out sports activities</u>: the use of the drug without therapeutic necessity constitutes doping and can however determine positivity to the tests antidoping.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding<sup> </sup></p><p>Do not take Aromasin if you are pregnant or breast-feeding.</p><p>If you are pregnant or think you might be, tell your doctor.</p><p>Discuss contraception with your doctor if there is any possibility that you may become pregnant.</p><p><strong>&nbsp;</strong></p><p>Driving and using machines</p><p>If you feel drowsy, dizzy or weak whilst taking Aromasin, you should not attempt to drive or operate machinery.</p><p>&nbsp;</p><p><strong>Aromasin contains sucrose, sodium and methyl parahydroxybenzoate</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aromasin contains a small amount of methyl parahydroxybenzoate, which may cause allergic reactions (possibly delayed), if this should happen please contact your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>AROMASIN treatment should be supervised by a physician experienced in the use of anti-cancer therapies.</p><p>&nbsp;</p><p>Tablets should be swallowed a whole.</p><p>&nbsp;</p><p><strong>Adults and the elderly patients</strong></p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>&nbsp;</p><p>Aromasin tablets should be taken by mouth after a meal at approximately the same time each day. Your doctor will tell you how to take Aromasin and for how long.</p><p>&nbsp;</p><p>The recommended dose is one 25 mg tablet daily.</p><p>&nbsp;</p><p>If you need to go to the hospital whilst taking Aromasin, let the medical staff know what medication you are taking.</p><p><strong>&nbsp;</strong></p><p><strong>Use in children</strong></p><p>Aromasin is not suitable for use in children.</p><p>&nbsp;</p><p>If you take more Aromasin than you should</p><p>If too many tablets are taken by accident, contact your doctor at once or go straight to the nearest hospital casualty department. Show them the pack of Aromasin tablets.</p><p>&nbsp;</p><p>If you forget to take Aromasin</p><p>Do not take a double dose to make up for a forgotten tablet.</p><p>&nbsp;</p><p>If you forget to take your tablet, take it as soon as you remember. If it is nearly time for the next dose, take it at the usual time.</p><p>&nbsp;</p><p><strong>If you stop taking Aromasin</strong></p><p>Do not stop taking your tablets even if you are feeling well, unless your doctor tells you.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Hypersensitivity, inflammation of the liver (hepatitis) and inflammation of the bile ducts of the liver which cause yellowing of the skin (cholestatic hepatitis) may occur. Symptoms include feeling generally unwell, nausea, jaundice (yellowing of the skin and eyes), itching, right sided abdominal pain and loss of appetite. Contact your doctor promptly to seek urgent medical advice if you think you have any of these symptoms.</p><p><em>&nbsp;</em></p><p>In general, Aromasin is well tolerated and the following side effects observed in patients treated with Aromasin are mainly mild or moderate in nature. Most of the side effects are associated with a shortage of oestrogen (e.g. hot flushes).</p><p><em>&nbsp;</em></p><p><strong>Very common: may affect more than 1 in 10 people</strong></p><p>&nbsp;</p><ul><li>Depression</li><li>Difficulty sleeping</li><li>Headache</li><li>Hot flushes</li><li>Dizziness</li><li>&nbsp;Feeling sick</li><li>Increased sweating</li><li>Muscle and joint pain (including osteoarthritis, back pain, arthritis and joint stiffness)</li><li>Tiredness</li><li>A reduction in the number of white blood cells</li><li>Abdominal pain</li><li>Elevated level of liver enzymes</li><li>Elevated level of a haemoglobin breakdown in the blood</li><li>Elevated level of a blood enzyme in the blood due to liver damage</li><li>Pain</li></ul><p>&nbsp;</p><p><strong>Common: may affect up to 1 in 10 people</strong></p><p>&nbsp;</p><ul><li>Loss of appetite</li><li>Carpal tunnel syndrome (a combination of pins and needles, numbness and pain affecting all of the hand except the little finger) or tingling/prickling of the skin</li><li>Vomiting (nausea), constipation, indigestion, diarrhoea</li><li>Hair loss</li><li>Skin rash, hives and itchiness</li><li>Thinning of bones which might decrease their strength (osteoporosis), leading to bone fractures (breaks or cracks) in some cases</li><li>Swollen hands and feet</li><li>A reduction in the number of platelets in the blood</li><li>Feeling of weakness</li></ul><p>&nbsp;</p><p><strong>Uncommon: may affect up to 1 in 100 people</strong></p><p>&nbsp;</p><ul><li>Hypersensitivity</li></ul><p>&nbsp;</p><p><strong>Rare: may affect up to 1 in 1,000 people</strong></p><p>&nbsp;</p><ul><li>A breakout of small blisters on an area of the skin in a rash</li><li>Drowsiness</li><li>Inflammation of the liver</li><li>Inflammation of the bile ducts of the liver which cause yellowing of the skin</li></ul><p>&nbsp;</p><p><strong>Not known: frequency cannot be estimated from the available data</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of certain white blood cells&nbsp;in the blood</p><p>&nbsp;</p><p>Changes in the amount of certain blood cells (lymphocytes) and platelets circulating in your blood, especially in patients with a pre-existing lymphopenia (reduced lymphocytes in the blood) may also be seen.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects including any possible side effects not listed in this leaflet, talk to your doctor or pharmacist. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp; Call Center: 19999</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 25 &deg;C</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shelf life 24 months</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the outer carton and the blister after EXP. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caution should be observed in handling broken, crushed, or opened capsules/tablets. Avoid direct contact with skin or mucous membranes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnant women should avoid exposure to AROMASIN tablets.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is exemestane.<strong><em> </em></strong>Each coated tablet contains 25 mg exemestane.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are silica colloidal hydrated, crospovidone, hypromellose, magnesium stearate, mannitol, microcrystalline cellulose, sodium starch glycolate (type&nbsp;A), polysorbate, polyvinyl alcohol, simeticone, macrogol, sucrose, magnesium carbonate light, methyl parahydroxybenzoate (E218), cetyl esters wax, talc, carnauba wax, ethyl alcohol, shellac, titanium oxide (E171) and iron oxides (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Aromasin is a round, biconvex, off-white to slightly greyish sugar-coated tablet marked 7663 on one side.
Aromasin is available in blister packs of 30 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder:</p><p>Pfizer Italia S.r.l., via Isonzo 71 &ndash; 04100 Latina</p><p>Italy.</p><p>&nbsp;</p><p>Manufacturer:</p><p>Pfizer Italia S.r.l</p><p>Localit&agrave; Marino del Tronto</p><p>63100<u> </u>Ascoli Piceno (AP),</p><p>Italy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2023.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُطلق على دوائكِ اسم أروماسين. ينتمي أروماسين إلى مجموعة أدوية تُعرف باسم مثبطات إنزيم الأروماتاز. تعارض هذه الأدوية عمل مادة تُسمى الأروماتاز، وهي مادة لازمة لصنع الهرمونات الجنسية الأنثوية، الإستروجينات، خاصةً في المرحلة التالية لانقطاع الحيض لدى السيدات. إن خفض مستويات الإستروجين في الجسم هو إحدى طرق علاج سرطان الثدي المعتمد على الهرمون.</p><p dir="RTL">يُستخدم أروماسين لعلاج سرطان الثدي المبكر المعتمد على الهرمون في المرحلة التالية لانقطاع الحيض لدى السيدات بعد أن يستكملن عامين إلى ٣ أعوام من العلاج بالدواء تاموكسيفين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم أروماسين أيضًا لعلاج سرطان الثدي المتقدم المعتمد على الهرمون في المرحلة التالية لانقطاع الحيض لدى السيدات عندما يفشل العلاج بعقار هرموني مختلف في العمل بدرجة كافية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال أروماسين:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp; إذا كنتِ مصابة أو أصبتِ من قبل بالحساسية تجاه إكزيمستين (المكون الفعال في أروماسين) أو أي مكون آخر من مكونات هذا الدواء (المدرجة بالقسم ٦).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا <strong>لم </strong>تكوني في &quot;فترة انقطاع الحيض&quot; بالفعل، أي ما زالت تأتيكِ الدورة الشهرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا، أو كان من المحتمل أن تكوني حاملًا، أو ترضعين رضاعة طبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال أروماسين</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدثي إلى طبيبكِ، أو الصيدلي، أو الممرضة قبل تناول أروماسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل العلاج بأروماسين، قد يرغب طبيبكِ في سحب عينات دم منكِ للتأكد من وصولكِ لفترة انقطاع الحيض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتم أيضًا إجراء فحص روتيني لقياس مستوى فيتامين د لديكِ قبل العلاج لأن مستواكِ قد يكون منخفضًا جدًا في المراحل المبكرة لسرطان الثدي. ستُعطى مكملًا لفيتامين د إذا كانت مستوياته لديكِ أقل من الطبيعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل تناول أروماسين، أبلغي طبيبك إذا كنتِ تعانين من مشكلات في كبدكِ أو كليتيكِ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبري طبيبكِ إذا كان لديكِ تاريخ من الإصابة أو إذا كنتِ تعانين من أي حالة تؤثر على قوة عظامكِ. قد يرغب طبيبكِ في قياس كثافة عظامكِ قبل وأثناء العلاج بأروماسين. وهذا لأن الأدوية التي تنتمي لهذه الفئة تقوم بخفض مستويات هرمونات الأنوثة وقد يؤدي هذا إلى فقدان المحتوى المعدني في العظام، وهو ما قد يقلل قوتها.&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبري طبيبكِ أو الصيدلي إذا كنتِ تتناولين أو تناولتِ مؤخرًا أو قد تتناولين أي أدوية أخرى، بما في ذلك الأدوية التي يمكن الحصول عليها دون وصفة طبية.</p><p dir="RTL">ينبغي عدم إعطاء أروماسين في نفس الوقت مع العلاج الهرموني التعويضي (HRT).</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي استخدام الأدوية التالية بحذر عند تناول أروماسين. أبلغي طبيبكِ إذا كنت تتناولين أدوية مثل:</p><ul><li dir="RTL">رِيفامبيسين (مضاد حيوي)،</li><li dir="RTL">كربامازيبين أو فينيتوين (مضادات تشنجات تستخدم لعلاج الصرع)،</li></ul><ul><li dir="RTL">العلاج العشبي نبتة سانت جون (هايبريكوم بيرفوراتوم) أو المستحضرات التي تحتوي عليها.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><u>بالنسبة للسيدات اللاتي يمارسن الأنشطة الرياضية</u>: يُعد استخدام العقار لغير ضرورة علاجية تناولًا للمنشطات، ومع ذلك يمكن أن يؤدي إلى نتيجة إيجابية في اختبارات الكشف عن المنشطات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">لا تتناولي أروماسين إذا كنتِ حاملًا أو تُرضعين رضاعة طبيعية.</p><p dir="RTL">إذا كنتِ حاملًا أو تعتقدين أنكِ قد تكونين حاملًا، فأخبري طبيبكِ.</p><p dir="RTL">ناقشي مسألة استخدام وسائل منع الحمل مع طبيبكِ إذا كانت هناك أي احتمالية أنكِ قد تصبحين حاملًا.</p><p dir="RTL">&nbsp;</p><p>تأثير أروماسين على القيادة واستخدام الآلات</p><p dir="RTL">إذا شعرتِ بالنعاس أو الدوار أو الضعف أثناء تناول أروماسين، ينبغي ألّا تحاولي القيادة أو تشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p>معلومات هامة حول بعض مكونات أروماسين</p><p>يحتوي أروماسين على السكروز، والصوديوم، وميثيل بارا هيدروكسي بنزوات</p><ul><li dir="RTL">إذا أخبركِ طبيبكِ أنكِ تعانين من عدم تحمل لبعض أنواع السكريات، فاتصلي بطبيبكِ قبل تناول هذا المنتج الدوائي.</li><li dir="RTL">يحتوي هذا الدواء على أقل من ١ مليمول من الصوديوم (٢٣ ملجم) لكل قرص، أي أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</li><li dir="RTL">يحتوي أروماسين على كمية صغيرة من ميثيل بارا هيدروكسي بنزوات الذي قد يسبب تفاعلات حساسية (يحتمل تأخرها)، يُرجى الاتصال بطبيبكِ إذا حدث هذا.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">ينبغي أن يشرف على العلاج بأروماسين طبيب خبير في استخدام العلاجات المضادة للسرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي ابتلاع القرص كاملًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المريضات البالغات والمسنات</strong></p><p dir="RTL">احرصي دائمًا على تناول هذا الدواء تمامًا كما أخبركِ طبيبكِ. راجعي طبيبكِ إذا كنتِ غير متأكدة مما ينبغي فعله.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ينبغي تناول أقراص أروماسين عن طريق الفم بعد تناول وجبة في نفس الأوقات تقريبًا كل يوم. سيخبركِ طبيبكِ بكيفية تناول أروماسين وطول فترة تناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تبلغ الجرعة الموصى بها قرصًا واحدًا ٢٥ ملجم يوميًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا احتجتِ للدخول إلى المستشفى أثناء تناول أروماسين، فأبلغي طاقم العمل الطبي بالأدوية التي تتناولينها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في الأطفال</strong></p><p dir="RTL">أروماسين غير مناسب للاستخدام مع الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من أروماسين</strong></p><p dir="RTL">في حالة تناول عدد أكبر مما ينبغي من الأقراص بشكل عرضي تواصلي مع طبيبكِ فورًا أو اذهبي مباشرةً لقسم الطوارئ في أقرب مستشفى. أظهري لهم عبوة أقراص أروماسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة أروماسين</strong></p><p dir="RTL">لا تتناولي جرعة مضاعفة لتعويض القرص الذي نسيتيه.</p><p dir="RTL">إذا نسيتِ تناول القرص المخصص لكِ، فتناوليه بمجرد تذكره. إذا كان موعد تناول الجرعة التالية وشيكًا، فتناوليها في الوقت المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول أروماسين</strong></p><p dir="RTL">لا تتوقفي عن تناول أقراصكِ حتى إذا كنتِ تشعرين أنكِ على ما يرام، ما لم يخبركِ طبيبكِ بفعل هذا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديكِ أي أسئلة إضافية حول استخدام هذا الدواء، فاسألي طبيبكِ أو الصيدلي أو الممرضة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب هذا الدواء في حدوث آثار جانبية، غير أنها لا تصيب الجميع</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يحدث فرط حساسية والتهاب الكبد والتهاب القنوات الصفراوية للكبد الذي يسبب اصفرار الجلد (التهاب الكبد الركودي). تشتمل الأعراض على شعور بالتوعك بشكل عام والغثيان واليرقان (اصفرار الجلد والعينين) والحكة وألم في الجانب الأيمن من البطن وفقدان الشهية. تواصلي مع طبيبكِ فورًا لطلب المشورة الطبية العاجلة إذا كنتِ تعتقدين أنكِ مصابة بأي من هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بشكل عام، إن تحمل أروماسين جيد، والآثار الجانبية التالية التي لوحظت في المريضات اللاتي تعالجن بأروماسين تكون بطبيعتها خفيفة أو متوسطة بشكلٍ أساسي. معظم الآثار الجانبية مرتبطة بنقص الإستروجين (مثل هبّات الحرارة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا: يمكن أن تصيب أكثر من سيدة واحدة من بين كل ١٠ سيدات</strong></p><ul><li dir="RTL">الاكتئاب</li><li dir="RTL">صعوبة النوم</li><li dir="RTL">الصداع</li><li dir="RTL">هبّات الحرارة</li><li dir="RTL">الدوار</li><li dir="RTL">الشعور بالغثيان</li><li dir="RTL">زيادة العرق</li><li dir="RTL">ألم العضلات والمفاصل (بما في ذلك الفصال العظمي، وألم الظهر، والتهاب المفاصل، وتيبس المفاصل)</li><li dir="RTL">التعب</li><li dir="RTL">انخفاض في عدد خلايا الدم البيضاء</li><li dir="RTL">ألم البطن</li><li dir="RTL">ارتفاع مستوى إنزيمات الكبد</li><li dir="RTL">ارتفاع مستوى انحلال الهيموجلوبين في الدم</li><li dir="RTL">ارتفاع مستوى إنزيم في الدم نتيجة لتلف الكبد</li><li dir="RTL">الألم</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة: يمكن أن تصيب ما يصل إلى سيدة واحدة من بين كل ١٠ سيدات</strong></p><ul><li dir="RTL">فقدان الشهية</li><li dir="RTL">متلازمة النفق الرسغي (الشعور بمزيج من الشكشكة والوخز، مع شعور بالتنميل والألم يصيب اليد كلها ما عدا الإصبع الصغير) أو الوخز/الشكشكة في الجلد</li><li dir="RTL">القيء (الغثيان)، الإمساك، عسر الهضم، الإسهال</li><li dir="RTL">تساقط الشعر</li><li dir="RTL">الطفح الجلدي، والشرى، والحكة</li><li dir="RTL">ترقق العظام الذي قد يُضعف قوتها (هشاشة العظام)، مما يؤدي إلى كسور في العظام (كسور أو شروخ) في بعض الحالات</li><li dir="RTL">تورم اليدين والقدمين</li><li dir="RTL">انخفاض عدد الصفيحات الدموية في الدم</li><li dir="RTL">الشعور بالضعف</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة: يمكن أن تصيب ما يصل إلى سيدة واحدة من بين كل ١٠٠ سيدة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><ul><li dir="RTL">فرط الحساسية</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة: يمكن أن تصيب ما يصل إلى سيدة واحدة من بين كل ١٠٠٠ سيدة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتشار بثور صغيرة في منطقة من الجلد على شكل طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القنوات الصفراوية للكبد الذي يؤدي إلى اصفرار الجلد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ذات معدل تكرار غير معروف: لا يمكن تقدير معدل التكرار من البيانات المتاحة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات نوع معين من خلايا الدم البيضاء في الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أيضًا ملاحظة تغيرات في كمية خلايا دم معينة (الليمفاويات) والصفائح الدموية الدائرة في مجرى الدم، خاصة لدى المريضات المصابات بالفعل بقلة الليمفاويات (انخفاض عدد الليمفاويات في الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبتِ بأي آثار جانبية، بما في ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة، فتحدثي إلى طبيبكِ أو الصيدلي. بالإبلاغ عن الآثار الجانبية، يمكنكِ المساعدة في توفير المزيد من المعلومات حول السلامة فيما يتعلق بهذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp; </strong><strong>مركز الاتصال الموحد: </strong>١٩٩٩٩</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp; </strong><strong>البريد الإلكتروني: </strong>npc.drug@sfda.gov.sa</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp; </strong><strong>الموقع الإلكتروني: </strong>https://ade.sfda.gov.sa<strong>&nbsp;&nbsp;</strong></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظي بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يخزن أقراص دوائكِ في درجة حرارة اقل من&nbsp; ٢٥ درجة مئوية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدة الصلاحيه:٢٤ شهرا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدمي هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية الخارجية وشريط البليستر بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي توخي الحذر عند التعامل مع الكبسولات/الأقراص المكسورة أو المسحوقة أو المفتوحة. تجنبي ملامسة الدواء للجلد أو الأغشية المخاطية مباشرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي للحوامل تجنب التعرض لأقراص أروماسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلصي من أي أدوية عبر مياه الصرف أو في القمامة المنزلية. اسألي الصيدلي عن كيفية التخلص من الأدوية التي لم تعودي تستخدمينها.&nbsp; ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي إكزيمستين. يحتوي كل قرص مغلّف على ٢٥ ملجم إكزيمستين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي سيليكا غروية مميهة، وكروسبوفيدون، وهيبروميلوز، وستيارات المغنيسيوم، ومانيتول، وسليولوز بلوري مكروي، وغليكولات النشاء الصودي (النوع أ)، وبولي سوربات، وكحول البولي فينيل، وسيميتيكون، وماكروجول سكروز، وكربونات المغنيسيوم الخفيفة، وبارا هيدروكسي بنزوات الميثيل (E218)، وشمع إسترات السيتيل، وتَلك، وشمع الكارنوبا، وكحول إيثيلي، وصمغ اللّك، وأكسيد التيتانيوم (E171)، وأكسيدات الحديد (E172).</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">أقراص أروماسين مستديرة محدبة الوجهينمغلفة بالسكر &nbsp;لونها مائل للأبيض إلى رمادي قليلًا وبها العلامة &quot;7663&quot; على أحد جانبيها.</p><p dir="RTL">يتوافر أروماسين في عبوات تحتوي على شرائط بليستر بها ٣٠ قرصًا.</p><p dir="RTL">&nbsp;&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>مالك رخصة التسويق:</p><p>Pfizer Italia S.r.l., via Isonzo 71 &ndash; 04100 Latina</p><p>Italy، إيطاليا.</p><p>&nbsp;</p><p>&nbsp;</p><p>الجهة المصنعة:</p><p>Pfizer Italia S.r.l</p><p>Localit&agrave; Marino del Tronto</p><p>63100 Ascoli Piceno (AP),</p><p>Italy، إيطاليا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            إبريل/نيسان ۲۰۲۳.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aromasin 25 mg coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active substance: exemestane

Each coated tablet contains 25 mg exemestane.

Excipients with known effect
Each tablet contains 30.19 mg of sucrose and 0.003 mg of methyl parahydroxybenzoate (E218). 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Coated tablet.
Round, biconvex, off-white to slightly greyish sugar-coated tablet marked 7663 on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer (EBC), following 2 &ndash; 3 years of initial adjuvant tamoxifen therapy.</p><p>&nbsp;</p><p>Aromasin is indicated for the treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.</p><p>Efficacy has not been demonstrated in patients with oestrogen receptor negative status.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p><em>Adult and elderly patients</em></p><p>The recommended dose of Aromasin is one 25 mg tablet to be taken once daily, preferably after a meal.</p><p>&nbsp;</p><p>In patients with early breast cancer, treatment with Aromasin should continue until completion of five years of combined sequential adjuvant hormonal therapy (tamoxifen followed by Aromasin), or earlier if tumour relapse occurs.</p><p>&nbsp;</p><p>In patients with advanced breast cancer, treatment with Aromasin should continue until tumour progression is evident.</p><p>&nbsp;</p><p>No dose adjustments are required for patients with hepatic or renal insufficiency (see section&nbsp;5.2).</p><p><u>&nbsp;</u></p><p><em>Paediatric population</em></p><p>Not recommended for use in children.</p><p>&nbsp;</p><p>AROMASIN treatment should be supervised by a physician experienced in the use of anti-cancer therapies.</p><p>Tablets should be swallowed a whole.</p><p>The tablets should not be broken or crushed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
In pre-menopausal women and in pregnant or lactating women.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aromasin should not be administered to women with pre-menopausal endocrine status. Therefore, whenever clinically appropriate, the post-menopausal status should be ascertained by assessment of LH, FSH and oestradiol levels.</p><p>&nbsp;</p><p>Aromasin should be used with caution in patients with hepatic or renal impairment.</p><p>&nbsp;</p><p>Aromasin tablets contain sucrose and should not be administered to patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.</p><p>&nbsp;</p><p>Aromasin tablets contain methyl parahydroxybenzoate which may cause allergic reactions (possibly delayed).</p><p>&nbsp;</p><p>Aromasin is a potent oestrogen lowering agent, and a reduction in bone mineral density (BMD) and an increased fracture rate have been observed following administration (see section 5.1). At the commencement of adjuvant treatment with Aromasin, women with osteoporosis or at risk of osteoporosis should have treatment baseline bone mineral health assessment based on current clinical guidelines and practice. Patients with advanced disease should have their bone mineral density assessed on a case-by-case basis. Although adequate data to show the effects of therapy in the treatment of the bone mineral density loss caused by Aromasin are not available, patients treated with Aromasin should be carefully monitored and treatment for, or prophylaxis of, osteoporosis should be initiated in at risk patients.</p><p>&nbsp;</p><p>Routine assessment of 25 hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be considered, due to the high prevalence of severe deficiency in women with early breast cancer. Women with Vitamin D deficiency should receive supplementation with Vitamin D.</p><p>&nbsp;</p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro</em> evidence showed that the drug is metabolised through cytochrome P450 CYP3A4 and aldoketoreductases (see section 5.2) and does not inhibit any of the major CYP isoenzymes. In a clinical pharmacokinetic study, the specific inhibition of CYP3A4 by ketoconazole showed no significant effects on the pharmacokinetics of exemestane.</p><p>&nbsp;</p><p>In an interaction study with rifampicin, a potent CYP450 inducer, at a dose of 600&nbsp;mg daily and a single dose of exemestane 25&nbsp;mg, the AUC of exemestane was reduced by 54% and Cmax by 41%. Since the clinical relevance of this interaction has not been evaluated, the co‑administration of medicinal products, such as rifampicin, anticonvulsants (e.g., phenytoin and carbamazepine) and herbal preparations containing hypericum perforatum (St John&rsquo;s Wort) known to induce CYP3A4 may reduce the efficacy of Aromasin.</p><p>&nbsp;</p><p>Aromasin should be used cautiously with medicinal products that are metabolised via CYP3A4 and have a narrow therapeutic window. There is no clinical experience of the concomitant use of Aromasin with other anticancer medicines.</p><p>&nbsp;</p><p>Aromasin should not be co-administered with oestrogen-containing medicines as these would negate its pharmacological action.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No clinical data on exposed pregnancies are available with Aromasin. Studies in animals have shown reproductive toxicity (see section 5.3). Aromasin is therefore contraindicated in pregnant women.</p><p><u>&nbsp;</u></p><p><u>Breast-feeding </u></p><p>It is unknown whether exemestane is excreted in human milk. Aromasin should not be administered to lactating woman.</p><p>&nbsp;</p><p><u>Women of perimenopausal status or child-bearing potential</u></p><p>The physician needs to discuss the necessity of adequate contraception with women who have the potential to become pregnant including women who are perimenopausal or who have recently become postmenopausal, until their postmenopausal status is fully established (see sections 4.3 and&nbsp;4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Exemestane has moderate influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>Drowsiness, somnolence, asthenia and dizziness have been reported with the use of exemestane. Patients should be advised that, if these events occur, their physical and/or mental abilities required for operating machinery or driving a car may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aromasin was generally well tolerated across all clinical studies conducted with Aromasin at a standard dose of 25&nbsp;mg/day, and undesirable effects were usually mild to moderate.</p><p>&nbsp;</p><p>The withdrawal rate due to adverse events was 7.4% in patients with early breast cancer receiving adjuvant treatment with Aromasin following initial adjuvant tamoxifen therapy. The most commonly reported adverse reactions were hot flushes (22%), arthralgia (18%) and fatigue (16%).</p><p>&nbsp;</p><p>The withdrawal rate due to adverse events was 2.8% in the overall patient population with advanced breast cancer. The most commonly reported adverse reactions were hot flushes (14%) and nausea&nbsp;(12%).</p><p>&nbsp;</p><p>Most adverse reactions can be attributed to the normal pharmacological consequences of oestrogen deprivation (e.g., hot flushes).</p><p>&nbsp;</p><p>The reported adverse reactions from clinical studies and post-marketing experience are listed below by system organ class and by frequency.</p><p>&nbsp;</p><p>Frequencies are defined as: Very common (&ge;1/10); Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1,000); Very rare (&lt;1/10,000); Not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Blood and lymphatic system disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Leucopenia<sup>(</sup>**<sup>)</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Thrombocytopenia<sup>(</sup>**<sup>)</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Not known</em></p></td><td style="vertical-align:top"><p>Lymphocyte count decreased<sup>(</sup>**<sup>)</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Immune system disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon</em></p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Metabolism and nutrition disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Anorexia</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Psychiatric disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Depression insomnia</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Nervous system disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Headache, dizziness</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Carpal tunnel syndrome, paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p>Somnolence</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Vascular disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Hot flushes</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Gastrointestinal disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Abdominal pain, nausea</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Vomiting, diarrhoea, constipation, dyspepsia,</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Hepatobiliary disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p>Hepatitis,<sup>(&dagger;)</sup> cholestatic hepatitis<sup>(&dagger;)</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Skin and subcutaneous tissue disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Alopecia, rash, urticaria, pruritus</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare</em></p></td><td style="vertical-align:top"><p>Acute generalised exanthematous pustulosis<sup>(&dagger;)</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Musculoskeletal and connective tissue disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Joint and musculoskeletal pain<sup>(</sup>*<sup>)</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Fracture, osteoporosis</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>General disorders and administration site conditions:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Very common</em></p></td><td style="vertical-align:top"><p>Pain, fatigue</p></td></tr><tr><td style="vertical-align:top"><p><em>Common</em></p></td><td style="vertical-align:top"><p>Oedema peripheral, asthenia</p></td></tr><tr><td style="vertical-align:top"><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Investigations:</em></strong></p><p><em>Very common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatic enzyme increased, blood bilirubin increased, blood alkaline phosphatase increased</em></p><p><strong><em>&nbsp;</em></strong></p></td></tr></tbody></table><p><sup>(</sup>*<sup>)</sup> Includes: arthralgia, and less frequently pain in extremity, osteoarthritis, back pain, arthritis, myalgia and joint stiffness.</p><p><sup>(</sup>**<sup>)</sup> In patients with advanced breast cancer thrombocytopenia and leucopenia have been rarely reported. An occasional decrease in lymphocytes has been observed in approximately<em> </em>20%<em> </em>of patients receiving Aromasin, particularly in patients with pre-existing lymphopenia; however, mean lymphocyte values in these patients did not change significantly over time and no corresponding increase in viral infections was observed. These effects have not been observed in patients treated in early breast cancer studies.</p><p><sup>(&dagger;) </sup>Frequency calculated by rule of 3/X.</p><p><strong>&nbsp;</strong></p><p>The table below presents the frequency of pre-specified adverse events and illnesses in the early breast cancer study Intergroup Exemestane Study (IES), irrespective of causality, reported in patients receiving trial therapy and up to 30 days after cessation of trial therapy.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>Adverse events and illnesses</strong></p></td><td><p><strong>Exemestane</strong></p><p><strong>(N = 2249)</strong></p></td><td><p><strong>Tamoxifen</strong></p><p><strong>(N = 2279)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Hot flushes</p></td><td style="vertical-align:top"><p>491 (21.8%)</p></td><td style="vertical-align:top"><p>457 (20.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>367 (16.3%)</p></td><td style="vertical-align:top"><p>344 (15.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>305 (13.6%)</p></td><td style="vertical-align:top"><p>255 (11.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>290 (12.9%)</p></td><td style="vertical-align:top"><p>204 (9.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Sweating increased</p></td><td style="vertical-align:top"><p>270 (12.0%)</p></td><td style="vertical-align:top"><p>242 (10.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Gynaecological</p></td><td style="vertical-align:top"><p>235 (10.5%)</p></td><td style="vertical-align:top"><p>340 (14.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>224 (10.0%)</p></td><td style="vertical-align:top"><p>200 (8.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>200 (8.9%)</p></td><td style="vertical-align:top"><p>208 (9.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Osteoporosis</p></td><td style="vertical-align:top"><p>116 (5.2%)</p></td><td style="vertical-align:top"><p>66 (2.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal haemorrhage</p></td><td style="vertical-align:top"><p>90 (4.0%)</p></td><td style="vertical-align:top"><p>121 (5.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Other primary cancer</p></td><td style="vertical-align:top"><p>84 (3.6%)</p></td><td style="vertical-align:top"><p>125 (5.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>50 (2.2%)</p></td><td style="vertical-align:top"><p>54 (2.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Visual disturbance</p></td><td style="vertical-align:top"><p>45 (2.0%)</p></td><td style="vertical-align:top"><p>53 (2.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Thromboembolism</p></td><td style="vertical-align:top"><p>16 (0.7%)</p></td><td style="vertical-align:top"><p>42 (1.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Osteoporotic fracture</p></td><td style="vertical-align:top"><p>14 (0.6%)</p></td><td style="vertical-align:top"><p>12 (0.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial infarction</p></td><td style="vertical-align:top"><p>13 (0.6%)</p></td><td style="vertical-align:top"><p>4 (0.2%)</p></td></tr></tbody></table><p>&nbsp;</p><p>In the IES study, the frequency of ischemic cardiac events in the exemestane and tamoxifen treatment arms was 4.5% versus 4.2%, respectively. No significant difference was noted for any individual cardiovascular event including hypertension (9.9% versus 8.4%), myocardial infarction (0.6% versus 0.2%) and cardiac failure (1.1% versus 0.7%).</p><p>&nbsp;</p><p>In the IES study, exemestane was associated with a greater incidence of hypercholesterolemia compared with tamoxifen (3.7% versus. 2.1%).</p><p>&nbsp;</p><p>In a separate double blinded, randomised study of postmenopausal women with early breast cancer at low risk treated with exemestane (N=73) or placebo (N=73)&nbsp;for 24&nbsp;months, exemestane was associated with&nbsp;an average 7-9% mean reduction in plasma HDL‑cholesterol, versus a 1% increase on placebo. There was also a&nbsp;5-6% reduction in apolipoprotein A1&nbsp;in the exemestane group versus 0-2% for placebo. The effect on the other lipid parameters analysed (total cholesterol, LDL cholesterol, triglycerides, apolipoprotein-B and lipoprotein-a) was very similar in the two treatment groups. The clinical significance of these results&nbsp;is unclear.</p><p>&nbsp;</p><p>In the IES study, gastric ulcer was observed at a higher frequency in the exemestane arm compared to tamoxifen (0.7% versus &lt;0.1%). The majority of patients on exemestane with gastric ulcer received concomitant treatment with non-steroidal anti-inflammatory agents and/or had a prior history.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after market authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local country requirements.</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical trials have been conducted with Aromasin given up to 800 mg in a single dose to healthy female volunteers and up to 600 mg daily to postmenopausal women with advanced breast cancer; these dosages were well tolerated. The single dose of Aromasin that could result in life-threatening symptoms is not known. In rats and dogs, lethality was observed after single oral doses equivalent respectively to 2000 and 4000 times the recommended human dose on a mg/m<sup>2</sup> basis.<strong> </strong>There is no specific antidote to overdosage and treatment must be symptomatic. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: steroidal aromatase inhibitor; anti-neoplastic agent, ATC: L02BG06</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Exemestane is an irreversible, steroidal aromatase inhibitor, structurally related to the natural substrate androstenedione. In post-menopausal women, oestrogens are produced primarily from the conversion of androgens into oestrogens through the aromatase enzyme in peripheral tissues. Oestrogen deprivation through aromatase inhibition is an effective and selective treatment for hormone dependent breast cancer in postmenopausal women. In postmenopausal women, Aromasin p.o. significantly lowered serum oestrogen concentrations starting from a 5&nbsp;mg dose, reaching maximal suppression (&gt;90%) with a dose of 10-25 mg. In postmenopausal breast cancer patients treated with the 25 mg daily dose, whole body aromatization was reduced by 98%.</p><p>&nbsp;</p><p>Exemestane does not possess any progestogenic or oestrogenic activity. A slight androgenic activity, probably due to the 17-hydro derivative, has been observed mainly at high doses. In multiple daily doses trials, Aromasin had no detectable effects on adrenal biosynthesis of cortisol or aldosterone, measured before or after ACTH challenge, thus demonstrating its selectivity with regard to the other enzymes involved in the steroidogenic pathway.</p><p>&nbsp;</p><p>Glucocorticoid or mineralocorticoid replacements are therefore not needed. A non dose‑dependent slight increase in serum LH and FSH levels has been observed even at low doses: this effect is, however, expected for the pharmacological class and is probably the result of feedback at the pituitary level due to the reduction in oestrogen levels that stimulate the pituitary secretion of gonadotropins also in postmenopausal women.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p><em><u>Adjuvant treatment of early breast cancer</u></em></p><p>In a multicentre, randomised, double-blind study (IES), conducted in 4724 postmenopausal patients with oestrogen-receptor-positive or unknown primary breast cancer, patients who had remained disease-free after receiving adjuvant tamoxifen therapy for 2 to 3 years were randomised to receive 3&nbsp;to 2 years of Aromasin (25 mg/day) or tamoxifen (20 or 30 mg/day) to complete a total of 5 years of hormonal therapy.</p><p>&nbsp;</p><p><em>IES 52-month median follow-up</em></p><p>After a median duration of therapy of about 30 months and a median follow-up of about 52&nbsp;months, results showed that sequential treatment with Aromasin after 2 to 3 years of adjuvant tamoxifen therapy was associated with a clinically and statistically significant improvement in disease-free survival (DFS) compared with continuation of tamoxifen therapy. Analysis showed that in the observed study period Aromasin reduced the risk of breast cancer recurrence by 24% compared with tamoxifen (hazard ratio 0.76; p=0.00015). The beneficial effect of exemestane over tamoxifen with respect to DFS was apparent regardless of nodal status or prior chemotherapy.</p><p>&nbsp;</p><p>Aromasin also significantly reduced the risk of contralateral breast cancer (hazard ratio 0.57, p&nbsp;=&nbsp;0.04158).</p><p>&nbsp;</p><p>In the whole study population, a trend for improved overall survival was observed for exemestane (222&nbsp;deaths) compared to tamoxifen (262 deaths) with a hazard ratio 0.85 (log‑rank test: p&nbsp;=&nbsp;0.07362), representing a 15% reduction in the risk of death in favour of exemestane. A statistically significant 23% reduction in the risk of dying (hazard ratio for overall survival 0.77; Wald&nbsp;chi square test: p&nbsp;=&nbsp;0.0069) was observed for exemestane compared to tamoxifen when adjusting for the pre‑specified prognostic factors (i.e., ER status, nodal status, prior chemotherapy, use of HRT and use of bisphosphonates).</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:602px"><tbody><tr><td colspan="5"><p><strong><u>52-month main efficacy results in all patients (intention to treat population) and oestrogen receptor positive patients</u></strong><strong>:</strong></p></td></tr><tr><td><p><strong>Endpoint</strong></p><p><strong>Population</strong></p></td><td><p><strong>Exemestane</strong></p><p><strong>Events /N (%)</strong></p></td><td><p><strong>Tamoxifen</strong></p><p><strong>Events /N (%)</strong></p></td><td><p><strong>Hazard Ratio (95% CI)</strong></p></td><td><p><strong>p-value*</strong></p></td></tr><tr><td colspan="5"><p><strong>Disease-free survival<em><sup> </sup></em><sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>All patients</p></td><td><p><strong>354</strong> /2352 (15.1%)</p></td><td><p><strong>453</strong> /2372 (19.1%)</p></td><td><p>0.76 (0.67-0.88)</p></td><td><p>0.00015</p></td></tr><tr><td style="vertical-align:top"><p>ER+ patients</p></td><td><p><strong>289</strong> /2023 (14.3%)</p></td><td><p><strong>370</strong> /2021 (18.3%)</p></td><td><p>0.75 (0.65-0.88)</p></td><td><p>0.00030</p></td></tr><tr><td colspan="5"><p><strong>Contralateral breast cancer</strong></p></td></tr><tr><td style="vertical-align:top"><p>All patients</p></td><td><p><strong>20</strong> /2352 (0.9%)</p></td><td><p><strong>35</strong> /2372 (1.5%)</p></td><td><p>0.57 (0.33-0.99)</p></td><td><p>0.04158</p></td></tr><tr><td style="vertical-align:top"><p>ER+ patients</p></td><td><p><strong>18</strong> /2023 (0.9%)</p></td><td><p><strong>33</strong> /2021 (1.6%)</p></td><td><p>0.54 (0.30-0.95)</p></td><td><p>0.03048</p></td></tr><tr><td colspan="5"><p><strong>Breast cancer free survival<sup> b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>All patients</p></td><td><p><strong>289</strong> /2352 (12.3%)</p></td><td><p><strong>373</strong> /2372 (15.7%)</p></td><td><p>0.76 (0.65-0.89)</p></td><td><p>0.00041</p></td></tr><tr><td style="vertical-align:top"><p>ER+ patients</p></td><td><p><strong>232</strong> /2023 (11.5%)</p></td><td><p><strong>305</strong> /2021 (15.1%)</p></td><td><p>0.73 (0.62-0.87)</p></td><td><p>0.00038</p></td></tr><tr><td colspan="5"><p><strong>Distant recurrence free survival<sup> c</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>All patients</p></td><td><p><strong>248</strong> /2352 (10.5%)</p></td><td><p><strong>297</strong> /2372 (12.5%)</p></td><td><p>0.83 (0.70-0.98)</p></td><td><p>0.02621</p></td></tr><tr><td style="vertical-align:top"><p>ER+ patients</p></td><td><p><strong>194</strong> /2023 (9.6%)</p></td><td><p><strong>242</strong> /2021 (12.0%)</p></td><td><p>0.78 (0.65-0.95)</p></td><td><p>0.01123</p></td></tr><tr><td colspan="5"><p><strong>Overall survival<sup> d</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>All patients</p></td><td><p><strong>222</strong> /2352 (9.4%)</p></td><td><p><strong>262</strong> /2372 (11.0%)</p></td><td><p>0.85 (0.71-1.02)</p></td><td><p>0.07362</p></td></tr><tr><td style="vertical-align:top"><p>ER+ patients</p></td><td><p><strong>178</strong> /2023 (8.8%)</p></td><td><p><strong>211</strong> /2021 (10.4%)</p></td><td><p>0.84 (0.68-1.02)</p></td><td><p>0.07569</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>* Log-rank test; ER+ patients = oestrogen receptor positive patients;</p><p><sup>a</sup> Disease-free survival is defined as the first occurrence of local or distant recurrence, contralateral breast cancer, or death from any cause;</p><p><sup>b</sup> Breast cancer free survival is defined as the first occurrence of local or distant recurrence, contralateral breast cancer or breast cancer death;</p><p><sup>c</sup> Distant recurrence free survival is defined as the first occurrence of distant recurrence or breast cancer death;</p><p><sup>d</sup> Overall survival is defined as occurrence of death from any cause.</p></td></tr></tbody></table><p>&nbsp;</p><p>In the additional analysis for the subset of patients with oestrogen receptor positive or unknown status, the unadjusted overall survival hazard ratio was 0.83 (log-rank test: p&nbsp;=&nbsp;0.04250), representing a clinically and statistically significant 17% reduction in the risk of dying.</p><p>&nbsp;</p><p>Results from the IES bone substudy demonstrated that women treated with Aromasin following 2 to 3&nbsp;years of tamoxifen treatment experienced moderate reduction in bone mineral density. In the overall study, the treatment emergent fracture incidence evaluated during the 30 months treatment period was higher in patients treated with Aromasin compared with tamoxifen (4.5% and 3.3% correspondingly, p&nbsp;=&nbsp;0.038).</p><p>&nbsp;</p><p>Results from the IES endometrial substudy indicate that after 2 years of treatment there was a median 33% reduction of endometrial thickness in the Aromasin-treated patients compared with no notable variation in the tamoxifen-treated patients. Endometrial thickening, reported at the start of study treatment, was reversed to normal (&lt;5 mm) for 54% of patients treated with Aromasin.</p><p><u>&nbsp;</u></p><p><em>IES 87-month median follow-up</em></p><p>After a median duration of therapy of about 30 months and a median follow-up of about 87&nbsp;months, results showed that sequential treatment with exemestane after 2 to 3 years of adjuvant tamoxifen therapy was associated with a clinically and statistically significant improvement in DFS compared with continuation of tamoxifen therapy. Results showed that in the observed study period Aromasin significantly reduced the risk of breast cancer recurrence by 16% compared with tamoxifen (hazard ratio 0.84; p&nbsp;=&nbsp;0.002).</p><p>&nbsp;</p><p>Overall, the beneficial effect of exemestane over tamoxifen with respect to DFS was apparent regardless of nodal status or prior chemotherapy or hormonal therapy. Statistical significance was not maintained in a few sub-groups with small sample sizes. These showed a trend favouring exemestane in patients with more than 9 nodes positive, or previous chemotherapy CMF. In patients with nodal status unknown, previous chemotherapy other, as well as unknown/missing status of previous hormonal therapy a non statistically significant trend favouring tamoxifen was observed.</p><p>&nbsp;</p><p>In addition, exemestane also significantly prolonged breast cancer-free survival (hazard ratio 0.82, p&nbsp;=&nbsp;0.00263) and distant recurrence-free survival (hazard ratio 0.85, p = 0.02425).</p><p><u>&nbsp;</u></p><p>Aromasin also reduced the risk of contralateral breast cancer, although the effect was no longer statistically significant in this observed study period (hazard ratio 0.74, p&nbsp;=&nbsp;0.12983). In the whole study population, a trend for improved overall survival was observed for exemestane (373 deaths) compared to tamoxifen (420 deaths) with a hazard ratio 0.89 (log&nbsp;rank test: p = 0.08972), representing an 11% reduction in the risk of death in favour of exemestane. When adjusting for the pre‑specified prognostic factors (i.e., ER status, nodal status, prior chemotherapy, use of HRT and use of bisphosphonates), a statistically significant 18% reduction in the risk of dying (hazard ratio for overall survival 0.82; Wald&nbsp;chi square test: p&nbsp;=&nbsp;0.0082) was observed for exemestane compared to tamoxifen<em> </em>in the whole study population</p><p>&nbsp;</p><p>In the additional analysis for the subset of patients with oestrogen receptor positive or unknown status, the unadjusted overall survival hazard ratio was 0.86 (log-rank test: p&nbsp;=&nbsp;0.04262), representing a clinically and statistically significant 14% reduction in the risk of dying.</p><p><u>&nbsp;</u></p><p>Results from a bone sub-study indicate that treatment with exemestane for 2 to 3&nbsp;years following 3&nbsp;to 2&nbsp;years of tamoxifen treatment increased bone loss while on treatment (mean % change from baseline for BMD at 36 months: -3.37 [spine], -2.96 [total hip] for exemestane and -1.29 [spine], ‑2.02 [total hip], for tamoxifen). However, by the end of the 24 month post treatment period there were minimal differences in the change in BMD from baseline for both treatment groups, the tamoxifen arm having slightly greater final reductions in BMD at all sites (mean % change from baseline for BMD at 24&nbsp;months post treatment ‑2.17 [spine], ‑3.06 [total hip] for exemestane and ‑3.44 [spine], -4.15 [total hip] for tamoxifen).</p><p>&nbsp;</p><p>The all fractures reported on-treatment and during follow-up was significantly higher in the exemestane group than on tamoxifen (169 [7.3%] versus 122 [5.2%]; p = 0.004), but no difference was noted in the number of fractures reported as osteoporotic.<strong><u> </u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><em>IES 119-month final follow-up</em></p><p>After a median duration of therapy of about 30 months and a median follow-up of about 119&nbsp;months, results showed that sequential treatment with exemestane after 2 to 3 years of adjuvant tamoxifen therapy was associated with a clinically and statistically significant improvement in DFS compared with continuation of tamoxifen therapy. Analysis showed that over the observed study period exemestane reduced the risk of breast cancer recurrence by 14% compared with tamoxifen (hazard ratio 0.86, p = 0.00393). The beneficial effect of exemestane over tamoxifen with respect to DFS was apparent regardless of nodal status or prior chemotherapy.</p><p>&nbsp;</p><p>Exemestane also significantly prolonged breast cancer-free survival (hazard ratio 0.83, p&lt;0.00152) and distant recurrence-free survival (hazard ratio 0.86, p = 0.02213). Exemestane also reduced risk of contralateral breast cancer; however, the effect was no longer statistically significant (hazard ratio 0.75, p = 0.10707).</p><p><s>&nbsp;</s></p><p>In the whole study population, overall survival was not statistically different between the two groups with 467 deaths (19.9%) occurring in the exemestane group and 510 deaths (21.5%) in the tamoxifen group (hazard ratio 0.91, p = 0.15737, not adjusted for multiple testing). For the subset of patients with oestrogen receptor positive or unknown status, the unadjusted overall survival hazard ratio was 0.89&nbsp;(log-rank test: p = 0.07881) in the exemestane group relative to the tamoxifen group.</p><p><s>&nbsp;</s></p><p>In the whole study population, a statistically significant 14% reduction in the risk of dying (hazard ratio for OS 0.86; Wald chi square test: p = 0.0257) was observed for exemestane compared with tamoxifen when adjusting for the pre-specified prognostic factors (i.e., ER status, nodal status, prior chemotherapy, use of HRT and use of bisphosphonates).</p><p><s>&nbsp;</s></p><p>A lower incidence of other second (non-breast) primary cancers was observed in exemestane‑treated patients compared with tamoxifen only-treated patients (9.9% versus 12.4%).</p><p>&nbsp;</p><p>In the main study, which had a median follow-up in all participants of 119 months (0&nbsp;‑&nbsp;163.94) and median duration&nbsp;of exemestane treatment of 30 months (0 &ndash; 40.41), the incidence of bone fractures was reported on&nbsp;169 (7.3%) patients in the exemestane group compared with 122 (5.2%) patients in the tamoxifen group&nbsp;(p=0.004).</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="7" style="vertical-align:top"><p>Efficacy Results From IES in Postmenopausal Women With Early Breast Cancer (ITT)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>No. of Events</p></td><td colspan="2" style="vertical-align:top"><p>Hazard Ratio</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Exemestane</p></td><td colspan="2" style="vertical-align:top"><p>Tamoxifen</p></td><td style="vertical-align:top"><p>Hazard Ratio</p></td><td style="vertical-align:top"><p>p-value</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>30-Month Median Treatment and 34.5-Month Median Follow-Up</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Disease-free survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_17822104044 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->a<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001B000000540062006C0046006E0054007800740042006B006D006B00490044005F00310037003800320032003100300034003000340034000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td colspan="2" style="vertical-align:top"><p>213</p></td><td style="vertical-align:top"><p>306</p></td><td style="vertical-align:top"><p>0.69 (95% CI: 0.58-0.82)</p></td><td style="vertical-align:top"><p>0.00003</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Breast cancer-free survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_1782210412 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->b<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001A000000540062006C0046006E0054007800740042006B006D006B00490044005F0031003700380032003200310030003400310032000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td colspan="2" style="vertical-align:top"><p>171</p></td><td style="vertical-align:top"><p>262</p></td><td style="vertical-align:top"><p>0.65 (95% CI: 0.54-0.79)</p></td><td style="vertical-align:top"><p>&lt;0.00001</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Contralateral breast cancer</p></td><td colspan="2" style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>0.32 (95% CI: 0.15-0.72)</p></td><td style="vertical-align:top"><p>0.00340</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Distant recurrence-free survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_17822104124 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->c<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001B000000540062006C0046006E0054007800740042006B006D006B00490044005F00310037003800320032003100300034003100320034000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td colspan="2" style="vertical-align:top"><p>142</p></td><td style="vertical-align:top"><p>204</p></td><td style="vertical-align:top"><p>0.70 (95% CI: 0.56-0.86)</p></td><td style="vertical-align:top"><p>0.00083</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Overall survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_17822104135 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->d<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001B000000540062006C0046006E0054007800740042006B006D006B00490044005F00310037003800320032003100300034003100330035000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td colspan="2" style="vertical-align:top"><p>116</p></td><td style="vertical-align:top"><p>137</p></td><td style="vertical-align:top"><p>0.86 (95% CI: 0.67-1.10)</p></td><td style="vertical-align:top"><p>0.22962</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>30-Month Median Treatment and 52-Month Median Follow-Up</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Disease-free survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_17822104044 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->a<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001B000000540062006C0046006E0054007800740042006B006D006B00490044005F00310037003800320032003100300034003000340034000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td style="vertical-align:top"><p>354</p></td><td colspan="2" style="vertical-align:top"><p>453</p></td><td style="vertical-align:top"><p>0.77 (95% CI: 0.67-0.88)</p></td><td style="vertical-align:top"><p>0.00015</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Breast cancer-free survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_1782210412 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->b<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001A000000540062006C0046006E0054007800740042006B006D006B00490044005F0031003700380032003200310030003400310032000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td style="vertical-align:top"><p>289</p></td><td colspan="2" style="vertical-align:top"><p>373</p></td><td style="vertical-align:top"><p>0.76 (95% CI: 0.65-0.89)</p></td><td style="vertical-align:top"><p>0.00041</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Contralateral breast cancer</p></td><td style="vertical-align:top"><p>20</p></td><td colspan="2" style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>0.57 (95% CI: 0.33-0.99)</p></td><td style="vertical-align:top"><p>0.04158</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Distant recurrence-free survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_17822104124 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->c<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001B000000540062006C0046006E0054007800740042006B006D006B00490044005F00310037003800320032003100300034003100320034000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td style="vertical-align:top"><p>248</p></td><td colspan="2" style="vertical-align:top"><p>297</p></td><td style="vertical-align:top"><p>0.83 (95% CI: 0.70-0.98)</p></td><td style="vertical-align:top"><p>0.02621</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Overall survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_17822104135 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->d<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001B000000540062006C0046006E0054007800740042006B006D006B00490044005F00310037003800320032003100300034003100330035000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td style="vertical-align:top"><p>222</p></td><td colspan="2" style="vertical-align:top"><p>262</p></td><td style="vertical-align:top"><p>0.85 (95% CI: 0.71-1.02)</p></td><td style="vertical-align:top"><p>0.07362</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>30-Month Median Treatment and 87-Month Median Follow-Up</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Disease-free survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_17822104044 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->a<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001B000000540062006C0046006E0054007800740042006B006D006B00490044005F00310037003800320032003100300034003000340034000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td style="vertical-align:top"><p>552</p></td><td colspan="2" style="vertical-align:top"><p>641</p></td><td style="vertical-align:top"><p>0.84 (95% CI: 0.75-0.94)</p></td><td style="vertical-align:top"><p>0.002</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Breast cancer-free survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_1782210412 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->b<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001A000000540062006C0046006E0054007800740042006B006D006B00490044005F0031003700380032003200310030003400310032000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td style="vertical-align:top"><p>434</p></td><td colspan="2" style="vertical-align:top"><p>513</p></td><td style="vertical-align:top"><p>0.82 (95% CI: 0.72-0.94)</p></td><td style="vertical-align:top"><p>0.00263</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Contralateral breast cancer</p></td><td style="vertical-align:top"><p>43</p></td><td colspan="2" style="vertical-align:top"><p>58</p></td><td style="vertical-align:top"><p>0.74 (95% CI: 0.50-1.10)</p></td><td style="vertical-align:top"><p>0.12983</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Distant recurrence-free survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_17822104124 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->c<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001B000000540062006C0046006E0054007800740042006B006D006B00490044005F00310037003800320032003100300034003100320034000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td style="vertical-align:top"><p>353</p></td><td colspan="2" style="vertical-align:top"><p>409</p></td><td style="vertical-align:top"><p>0.85 ((95% CI: 0.74-0.98)</p></td><td style="vertical-align:top"><p>0.02425</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Overall survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_17822104135 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->d<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001B000000540062006C0046006E0054007800740042006B006D006B00490044005F00310037003800320032003100300034003100330035000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td style="vertical-align:top"><p>373</p></td><td colspan="2" style="vertical-align:top"><p>420</p></td><td style="vertical-align:top"><p>0.89 (95% CI: 0.77-1.02)</p></td><td style="vertical-align:top"><p>0.08972</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>30-Month Median Treatment and 119-Month Median Follow-Up</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Disease-free survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_17822104044 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->a<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001B000000540062006C0046006E0054007800740042006B006D006B00490044005F00310037003800320032003100300034003000340034000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td style="vertical-align:top"><p>672</p></td><td colspan="2" style="vertical-align:top"><p>761</p></td><td style="vertical-align:top"><p>0.86 (95% CI: 0.77-0.95)</p></td><td style="vertical-align:top"><p>0.00393</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Breast cancer-free survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_1782210412 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->b<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001A000000540062006C0046006E0054007800740042006B006D006B00490044005F0031003700380032003200310030003400310032000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td style="vertical-align:top"><p>517</p></td><td colspan="2" style="vertical-align:top"><p>608</p></td><td style="vertical-align:top"><p>0.83 (95% CI: 0.74-0.93)</p></td><td style="vertical-align:top"><p>0.00152</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Contralateral breast cancer</p></td><td style="vertical-align:top"><p>57</p></td><td colspan="2" style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>0.75 (95% CI: 0.53-1.06)</p></td><td style="vertical-align:top"><p>0.10707</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Distant recurrence-free survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_17822104124 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->c<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001B000000540062006C0046006E0054007800740042006B006D006B00490044005F00310037003800320032003100300034003100320034000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td style="vertical-align:top"><p>411</p></td><td colspan="2" style="vertical-align:top"><p>472</p></td><td style="vertical-align:top"><p>0.86 (95% CI: 0.75-0.98)</p></td><td style="vertical-align:top"><p>0.02213</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Overall survival<!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span> REF
  TblFnTxtBkmkID_17822104135 \h<span style='mso-spacerun:yes'>  </span>\*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->d<!--[if gte mso 9]><xml>
   <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001B000000540062006C0046006E0054007800740042006B006D006B00490044005F00310037003800320032003100300034003100330035000000</w:data>
  </xml><![endif]--><!--[if supportFields]><span
  class=MsoFootnoteReference><span lang=EN-GB style='mso-bidi-font-family:"Times New Roman";
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></span><![endif]--></p></td><td style="vertical-align:top"><p>467</p></td><td colspan="2" style="vertical-align:top"><p>510</p></td><td style="vertical-align:top"><p>0.91 (95% CI: 0.81-1.04)</p></td><td style="vertical-align:top"><p>0.15737</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>CI = confidence interval; IES = Intergroup Exemestane Study; ITT = intention-to-treat.</p><p><!--[if supportFields]><span
  lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span><span
  style='mso-spacerun:yes'> </span>SEQ TblFnSeqID_17822104044 \n \* alphabetic
  \* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->a<!--[if supportFields]><span
  lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]-->.&nbsp;&nbsp;&nbsp;&nbsp; Disease-free survival is defined as the first occurrence of local or distant recurrence, contralateral breast cancer or death from any cause.</p><p><!--[if supportFields]><span
  lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span><span
  style='mso-spacerun:yes'>  </span>SEQ TblFnSeqID_17822104044 \n \* alphabetic
  \* MERGEFORMAT<span style='mso-spacerun:yes'>  </span><span style='mso-element:
  field-separator'></span></span><![endif]-->b<!--[if supportFields]><span lang=EN-GB style='mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]-->.&nbsp;&nbsp;&nbsp; Breast cancer-free survival is defined as the first occurrence of local or distant recurrence, contralateral breast cancer or breast cancer death.</p><p><!--[if supportFields]><span
  lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span><span
  style='mso-spacerun:yes'>  </span>SEQ TblFnSeqID_17822104044 \n \* alphabetic
  \* MERGEFORMAT<span style='mso-spacerun:yes'>  </span><span style='mso-element:
  field-separator'></span></span><![endif]-->c<!--[if supportFields]><span lang=EN-GB style='mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]-->.&nbsp;&nbsp;&nbsp;&nbsp; Distant recurrence-free survival is defined as the first occurrence of distant recurrence or breast cancer death.</p><p><!--[if supportFields]><span
  lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span><span
  style='mso-spacerun:yes'>  </span>SEQ TblFnSeqID_17822104044 \n \* alphabetic
  \* MERGEFORMAT<span style='mso-spacerun:yes'>  </span><span style='mso-element:
  field-separator'></span></span><![endif]-->d<!--[if supportFields]><span lang=EN-GB style='mso-ansi-language:
  EN-GB'><span style='mso-element:field-end'></span></span><![endif]-->.&nbsp;&nbsp;&nbsp; Overall survival is defined as occurrence of death from any cause.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong><u>&nbsp;</u></strong></p><p><s>&nbsp;</s></p><p><em><u>Treatment of advanced breast cancer</u></em></p><p>In a randomised peer reviewed controlled clinical trial, Aromasin at the daily dose of 25 mg has demonstrated statistically significant prolongation of survival, Time to Progression (TTP), Time to Treatment Failure (TTF) as compared to a standard hormonal treatment with megestrol acetate in postmenopausal patients with advanced breast cancer that had progressed following, or during, treatment with tamoxifen either as adjuvant therapy or as first-line treatment for advanced disease.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After oral administration of Aromasin tablets, exemestane is absorbed rapidly. The fraction of the dose absorbed from the gastrointestinal tract is high. The absolute bioavailability in humans is unknown, although it is anticipated to be limited by an extensive first pass effect. A similar effect resulted in an absolute bioavailability in rats and dogs of 5%. After a single dose of 25 mg, maximum plasma levels of 18&nbsp;ng/ml are reached after 2 hours. Concomitant intake with food increases the bioavailability by 40%.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The volume of distribution of exemestane, not corrected for the oral bioavailability, is ca 20000 l. The kinetics is linear and the terminal elimination half-life is 24 h. Binding to plasma proteins is 90% and is concentration independent. Exemestane and its metabolites do not bind to red blood cells.</p><p>&nbsp;</p><p>Exemestane does not accumulate in an unexpected way after repeated dosing.</p><p><strong>&nbsp;</strong></p><p><u>Elimination</u></p><p>Exemestane is metabolised by oxidation of the methylene moiety on the 6 position by CYP3A4 isoenzyme and/or reduction of the 17-keto group by aldoketoreductase followed by conjugation. The clearance of exemestane is ca 500 l/h, not corrected for the oral bioavailability. The metabolites are inactive or the inhibition of aromatase is less than the parent compound. The amount excreted unchanged in urine is 1% of the dose. In urine and faeces equal amounts (40%) of <sup>14</sup>C-labeled exemestane were eliminated within a week.<br />&nbsp;</p><p><u>Special populations</u></p><p><strong>&nbsp;</strong></p><p><em>Age</em></p><p>No significant correlation between the systemic exposure of Aromasin and the age of subjects has been observed.</p><p><strong>&nbsp;</strong></p><p><em>Renal impairment</em></p><p>In patients with severe renal impairment (CL<sub>cr</sub> &lt;30 ml/min) the systemic exposure to exemestane was 2 times higher compared with healthy volunteers. Given the safety profile of exemestane, no dose adjustment is considered to be necessary.<br />&nbsp;</p><p><em>Hepatic impairment</em></p><p>In patients with moderate or<strong> </strong>severe hepatic impairment the exposure of exemestane is 2-3 fold higher compared with healthy volunteers.<strong> </strong>Given the safety profile of exemestane, no dose adjustment is considered to be necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Toxicological studies</u></p><p>Findings in the repeat dose toxicology studies in rat and dog were generally attributable to the pharmacological activity of exemestane, such as effects on reproductive and accessory organs. Other toxicological effects (on liver, kidney or central nervous system) were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.</p><p>&nbsp;</p><p><u>Mutagenicity</u></p><p>Exemestane was not genotoxic in bacteria (Ames test), in V79 Chinese hamster cells, in rat hepatocytes or in the mouse micronucleus assay. Although exemestane was clastogenic in lymphocytes<em> in vitro</em>, it was not clastogenic in two <em>in vivo</em> studies.</p><p><em>&nbsp;</em></p><p><u>Reproductive toxicology</u></p><p>Exemestane was embryotoxic in rats and rabbits at systemic exposure levels similar to those obtained in humans at 25 mg/day. There was no evidence of teratogenicity.</p><p>&nbsp;</p><p><u>Carcinogenicity</u></p><p>In a two-year carcinogenicity study in female rats, no treatment-related tumours were observed. In male rats the study was terminated on week 92, because of early death by chronic nephropathy. In a two-year carcinogenicity study in mice, an increase in the incidence of hepatic neoplasms in both genders was observed at the intermediate and high doses (150 and 450 mg/kg/day). This finding is considered to be related to the induction of hepatic microsomal enzymes, an effect observed in mice but not in clinical studies. An increase in the incidence of renal tubular adenomas was also noted in male mice at the high dose (450&nbsp;mg/kg/day). This change is considered to be species- and gender‑specific and occurred at a dose which represents 63-fold greater exposure than occurs at the human therapeutic dose. None of these observed effects is considered to be clinically relevant to the treatment of patients with exemestane.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u>: Silica colloidal hydrated; Crospovidone; Hypromellose; Magnesium stearate; Mannitol; Microcrystalline cellulose; Sodium starch glycolate (Type A); polysorbate.</p><p><u>&nbsp;</u></p><p><u>Sugar-coating</u>: Hypromellose; Polyvinylalcohol; Simeticone; Macrogol; Sucrose; Magnesium carbonate, light; Titanium dioxide(E171); Methyl parahydroxybenzoate (E218); Cetyl esters wax; Talc; Carnauba wax.</p><p><u>&nbsp;</u></p><p><u>Printing ink</u>: Ethyl alcohol; Shellac; Iron oxides (E172), Titanium oxide (E171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life: 24 months 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25 &deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>30 tablets in blister packs (Aluminium-PVDC/PVC-PVDC)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In healthcare settings, use designated area for medication storage and restrict access to only authorized personal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The tablets should not be divided, broken or crushed. This might produce powder that can contaminate workplace surfaces.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caution should be observed in handling broken or crushed tablets; wear double chemotherapy gloves and place in double bag or in a sealed container. Avoid direct contact with skin or mucous membranes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Personnel who are pregnant should avoid exposure to crushed or broken coated tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wear double gloves and protective gown for any disposal or cleaning activity of medication contaminated waste.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pfizer Italia S.r.l. 
Via Isonzo, 
71 – 04100 Latina 
Italy

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>